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Correct treatment of tuberculosis (TB) aims at
curing the individual patient, interrupting trans-
mission of TB to other persons, and preventing
bacilli from becoming drug resistant. These aims
are not achieved in many regions of the world even
when antituberculosis drugs are available [1]. The
main reasons are death of the patients during
treatment, default before the scheduled end of
treatment or resistance to the drugs prescribed.
Patient non-adherence to treatment is interpreted
as a failure of the health care system to cope with
the natural tendency of humans to quit treatment
as soon as they feel subjectively better, or better
without treatment if adverse drug events super-
vene [2]. 
Treatment outcome results serve as a proxy of
the quality of TB treatment provided by a health
care system. Recommendations on how to evalu-
ate treatment outcomes using standardised cate-
gories have been issued by the World Health Or-
ganization (WHO) in conjunction with the Euro-
pean Region of the International Union Against
Tuberculosis and Lung Disease (IUATLD) [3].
These categories were defined to assess the risk of
future relapse and drug resistance. Ideally, treat-
ment outcomes in all patients should be routinely
monitored by the epidemiological surveillance sys-
tem. This would make it possible to recognise and
amend system failures before the incidence and
proportion of resistant isolates rise. 
In Switzerland, notification of TB cases to the
health authorities is mandatory for both physicians
and laboratories, and laboratories are required to
report the results of testing of susceptibility to the
four first-line antituberculosis drugs. Outpatient
treatment of TB is predominantly in the hands of
private practitioners in Switzerland. Treatment
guidelines of the Swiss Lung Association exist [4].
Contrary to WHO/IUATLD recommendations,
however, TB treatment outcome results do not
Principles: Adequate treatment of pulmonary
tuberculosis cures patients and reduces transmis-
sion. The study assesses treatment outcomes under
current conditions in Switzerland.
Methods: Retrospective cohort study including
all TB cases with positive sputum cultures notified
to the national surveillance system between July
1996 and June 1997. Ten months after notification,
treating physicians reported the outcomes using
WHO categories.
Results: Of 265 patients, 209 (79%) completed
at least 6 months’ treatment, 3 (1%) were treat-
ment failures, 23 (9%) died, 8 (3%) defaulted from
treatment and 22 (8%) left the country. The pro-
portion of successful treatments did not signifi-
cantly differ between the 103 Swiss-born (80%)
and the 162 foreign-born (78%) patients. There
were 19 deaths (18%) in the Swiss-born and 4 (2%)
in the foreign-born groups; death was caused by
TB in two patients, 10 died of other causes (cause
unknown in 11). In the foreign-born group there
were 31 (19%) potentially unsatisfactory outcomes
(treatment failure, default from treatment, trans-
fer abroad) and in the Swiss-born group 2 (2%).
Default from treatment involved 8 patients, 6 of
whom were asylum seekers. In a multivariate
analysis potentially unsatisfactory outcomes were
not significantly associated with foreign origin but
with status as a foreigner of irregular or unknown
legal status (adj. OR 8.8; 95% CI 1.4 to 53.7).
Conclusions: Overall treatment success rates are
satisfactory and similar to those of other western
European countries. Potentially unsatisfactory
outcomes are more common in foreign-born per-
sons of irregular legal status. Tracking of non-ad-
herent patients by health workers could further
improve outcomes.
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Introduction
have to be reported under the current regulations.
The notification rate decreased to a historical low
of 9 cases per 100’000 population in the year 2000
[5]. The proportion of strains resistant to isoniazid
remained 6% between the years 1996 and 2000,
and the proportion of multidrug-resistant strains,
i.e. strains resistant at least to isoniazid and ri-
fampicin, between 1% and 2% [5, 6]. Resistances
were predominantly observed in foreign-born pa-
tients having already received treatment for tuber-
culosis in the past [6]. The TB situation in Switzer-
land is similar to that in several other European
countries [7–9]. 
Local surveys had prompted suspicion that
WHO targets for treatment outcomes were not
being met in Switzerland, but data representative
for the whole country were lacking [10, 11]. The
objectives of the present study therefore were to
ascertain the treatment outcomes in possibly con-
tagious TB patients countrywide, identify groups
at risk for unsatisfactory outcomes, obtain treat-
ment outcome results for immigrants subject to
the Federal screening programme, and evaluate
the feasibility of routine monitoring of treatment
outcomes. This would ultimately orient public
health authorities and practitioners regarding the
possible need for additional measures.
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Methods
The study included all TB patients notified to the
Swiss Federal Office of Public Health between 1 July 1996
and 30 June 1997 for pulmonary TB with a positive spu-
tum smear or a positive culture from sputum. 
Ten months after notification, standardised question-
naires were sent, via the cantonal public health authori-
ties, to the treating physicians who had notified the cases.
Treatment outcome at 6 months after the start of treat-
ment was the study endpoint. If a patient continued treat-
ment with another physician, the questionnaire was also
sent to the latter until the information was available for at
least the first 6 months of treatment. Patients who con-
tinued treatment beyond 6 months were classified as hav-
ing completed treatment. To ensure that the duration of
treatment was assessed correctly, information on the total
duration of treatment with each antituberculosis drug was
sought. In the event of non-response a reminder was sent
to the physician, followed by a telephone contact. 
The information gathered in this study was linked on
a case-by-case basis to that from physicians and labora-
tories already existing in the national TB database. Pre-
existing information concerned geographic origin, legal
status, previous antituberculosis treatment, organs affected
and antituberculosis drug resistance. Geographic origin of
patients was defined by country of birth [12], and if un-
known by nationality. Patients who had been treated in the
past were known either from the current notification or
from a previous patient record in the national TB registry.
The outcome categories of the WHO and IUATLD
working group were used [3]. There being no national TB
programme supervising treatment and routinely collect-
ing treatment results in Switzerland, adaptations in the
definitions of some outcomes were necessary (table 1).
The treatment outcomes were further grouped into three
summary categories (table 1): “successful”, i.e. the treat-
ment was such that the risk of relapse is minimal; “death”;
and “potentially unsatisfactory”, i.e. associated, or poten-
tially associated, with a higher risk of relapse or resistance
[3]. This separates the category “death” from the other
two, as deaths in low incidence countries are more often
deaths with TB as a second diagnosis than deaths due to
TB [8, 9]. The two remaining categories are epidemio-
logically relevant: cases with “successful outcomes” are
likely not to be transmitting TB any longer and cases with
“potentially unsatisfactory outcomes” may transmit a TB
strain that has possibly become resistant.
Category definitions of outcomes study adaptations of WHO/IUATLD summary categories 
for culture confirmed definition [rationale for adaptation] (WHO/IUATLD)
TB (WHO/IUATLD) [3]
Cured documented conversion of culture during same as WHO successful
the continuation phase
Treatment documented treatment completion, documented completion of 6 months’  
completed but no documented culture conversion treatment, but no documented culture  
conversion [at ten months’ follow-up  
some patients were still on treatment]
Death death of the patient irrespective of cause same as WHO death
at any time before scheduled end of treatment
Treatment culture remaining or again becoming positive same as WHO potentially unsatisfactory
failure at 5 months of treatment or later
Treatment patient off treatment for 2 consecutive months patient interrupted treatment without   
interrupted or more or failure to complete treatment within notice [intended regimen is not known  
9 months for a 6–month or within 12 months and interruption time cannot be reliably  
for a 9–month regimen or drug intake <80% sought from physicians]
Transfer out a patient referred to another clinician for patient went abroad, with or without 
treatment on whom information on treatment indication as to continuation of treatment, 
outcome cannot be obtained and no further information available 
[information on all patients remaining 
in Switzerland was available]
Table 1
Outcome categories
and definitions.
As the treatment of tuberculosis is in the hands of pri-
vate physicians, there is currently no legal or mandatory
control on the management of the disease (control of ad-
herence to treatment, bacteriological control during
treatment, tracing of non-compliant patients). Therefore,
the study reflects current conditions in Switzerland.
Logistic regression was used to test the effects of age,
sex, geographic origin, and legal status on treatment out-
come at 6 months. The dependent variable was “poten-
tially unsatisfactory treatment outcome” (n = 33). Deaths
were excluded from the analysis (n = 23). In the first phase
only one predicting variable was included in the model.
Then a main effects model including all predictors was es-
timated. All interaction terms additionally included in the
main effects model were insignificant. The results are pre-
sented as odds ratios and their 95% confidence intervals
(95% CI). These computations were done by Splus 2000
for Windows NT (MathSoft, Seattle, WA, USA).
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Results
During the period considered, 271 patients
were notified with positive sputum results, i.e.
either a positive microscopy or culture or both.
Their treating physicians could be located and all
eventually responded (response rate 100%). Of the
271 cases, 265 were confirmed by culture for M.
tuberculosis complex in at least one of the specimens
received by the laboratory, and were thus analysed.
Six cases were excluded because the cultures were
negative. 
176 patients (66%) were male and 89 (34%),
female. 150 were born in a foreign country and 81
in Switzerland, while in 34 patients information on
geographic origin was lacking; 22 of the latter had
Swiss nationality and 12 were foreign nationals.
Recoding the 34 “country of birth unknown” using
nationality, 162 (61%) were considered foreign-
born and 103 (39%) Swiss-born. The median age
was 38 years (range 1–99 years) overall. It was 67
years in Swiss-born subjects (range 1–94) and 30
years in foreign-born subjects (range 4 to 99). Di-
rect sputum microscopy was positive in 177 cases
(67%) and negative in 42 (16%); no information
available in 46 (17%). An extrapulmonary site was
additionally affected in 52 patients (20%). There
were 193 new cases, 30 were relapses and infor-
mation on prior treatment was unavailable in 42. 
Overall, treatment outcome at 6 months after
the start of treatment was successful in 209 patients
(79%) (table 2). There were 23 deaths either be-
fore or within six months following the start of
treatment. In three patients cultures were still pos-
itive after five months’ treatment or later. Eight
patients defaulted from treatment. Overall, 22 pa-
tients left the country either before (n = 11) or after
(n = 11) the start of treatment; an intention to begin
treatment abroad was known for one patient. 
Patients with a history of a previous treatment
Outcome (adapted N % (95% CI)
from WHO/IUATLD)
Total 265 100
Successful 209 79 (73 to 84)
cured 78 29 (24 to 35)
treatment completed 131 49 (43 to 56)
Death 23 9 (6 to 13)
Potentially unsatisfactory 33 12 (9 to 17)
treatment failure 3 1 (0 to 4)
treatment interrupted 8 3 (1 to 6)
transfer out 22 8 (5 to 12)
Table 2
Treatment outcome
at 6 months after
the start of antituber-
culosis treatment.
Outcome new cases recurrent cases previous treatment male female
unknown
Successful 156 (81%) 23 (77%) 30 (71%) 137 (78%) 72 (81%)
Death 15 (8%) 3 (10%) 5 (12%) 19 (11%) 4 (4%)
Potentially 22 (11%) 4 (13%) 7 (17%) 20 (11%) 13 (14%)
unsatisfactory
Total 193 (100%) 30 (100%) 42 (100%) 176 (100%) 89 (100%)
Table 3
Treatment outcome
by history of previ-
ous TB treatment 
and sex.
age group (years)
Outcome 1 to 27 28 to 39 40 to 66 67 to 99
Successful 56 (81%) 55 (80%) 55 (87%) 43 (67%)
Death 0 (0%) 0 (0%) 5 (8%) 18 (28%)
Potentially unsatisfactory 13 (19%*) 14 (20%*) 3 (5%) 3 (5%)
failure 1 (1%) 1 (2%) 0 1 (2%)
interrupted 3 (4%) 5 (7%) 0 0 
transfer out 9 (13%) 8 (12%) 3 (5%) 2 (3%)
Total 69 (100%) 69 (100%) 63 (100%) 64 (100%)
Table 4 
Outcome by age
(quartiles of age 
distribution).
for TB were analysed separately. There were no
significant differences of outcome depending on a
history of previous treatment or sex (table 3).
The proportion of successful treatment out-
comes was similar in all age groups (table 4). The
remaining outcomes differed: potentially unsatis-
factory outcomes were more frequent below age
40 than above. More deaths occurred above age 39.
The age range of the 23 deaths was 41–94 years
with a median of 74 years. Of the five deaths in the
age group between 40 and 66, three were foreign-
born patients. In the age group above 66 years, all
deaths except one occurred in Swiss-born patients.
One Swiss-born patient (aged 68) died from TB
and one foreign-born (aged 41) died of HIV-TB.
Ten patients died from other diseases than TB and
in 11 patients the cause of death was unknown. 
The proportions of successful outcomes were
similar in Swiss and foreign-born patients (table 5).
The proportion of deaths was higher in Swiss-born
patients, whereas potentially unsatisfactory out-
comes occurred more frequently in the foreign-
born. 
The legal status of TB cases is routinely col-
lected in the national TB database, as there are
Federal screening programmes for asylum seekers,
refugees, and foreign labour. The proportion of
successful outcomes was similar among Swiss na-
tionals, foreign labour and asylum seekers/
refugees (table 6). It was lower among foreigners
of other (visitors, students, retired persons, etc.) or
unknown legal status. Patients of the last-men-
tioned legal category had the highest proportion
of potentially unsatisfactory outcomes: all 16 were
“transfers out” abroad, two known to be involun-
tary. Among the eight asylum seekers or refugees
with a potentially unsatisfactory outcome, six de-
faulted from treatment by disappearing. 
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Outcome Swiss-born foreign-born
N % (95% CI) N % (95% CI)
Successful 82 80 (71 to 87) 127 78 (71 to 84)
Death 19 18 (11 to 27) 4 2 (1 to 6)
Potentially 2 2 (0 to 7) 31 19 (13 to 26)
unsatisfactory
Total 103 100 162 100
Table 5
Treatment outcome
by geographical 
origin of patients.
Outcome Swiss nationality asylum seekers and foreign workers foreigners of other 
refugees or unknown status
Successful 91 (81%) 42 (81%) 56 (89%) 20 (54%)
Death 19 (17%) 2 (4%) 1 (2%) 1 (3%)
Potentially 3 (3%) 8 (15%) 6 (10%) 16 (43%)
unsatisfactory
Failure 1 (1%) 1 (2%) 1 (2%) 0
Default 1 (1%) 6 (12%) 1 (2%) 0
Transfer out 1 (1%) 1 (2%) 4 (6%) 16 (43%)
Total 113 (100%) 52 (100%) 63 (100%) 37 (100%)
Table 6
Treatment outcome
and legal status.
univariate multivariate
crude OR 95% CI adj. OR 95% CI
Age (years) 1 to 27 1 1
28 to 39 1.1 (0.5 2.5) 1.4 (0.5 3.6)
40 to 66 0.2 (0.1 0.9) 0.4 (0.1 1.6)
67 to 99 0.3 (0.1 1.1) 0.7 (0.1 3.1)
Sex female 1 1
male 0.9 (0.6 1.3) 0.9 (0.6 1.4)
Geographic origin Swiss-born 1 1
foreign-born 3.2 (1.5 6.5) 1.8 (0.7 5.1)
Legal status Swiss 1 1
foreign workers 3.2 (0.8 13.4) 1.1 (0.2 7.2)
asylum seekers and refugees 5.8 (1.5 22.8) 1.9 (0.3 12.9)
others and unknown 24.3 (6.5 90.8) 8.8 (1.4 53.7)
Table 7
Predictors of poten-
tially unsatisfactory
outcomes in logistic
regression models. 
The logistic regression models confirmed the
above findings. In the simple models age, geo-
graphic origin and legal status were significant pre-
dictors of a potentially unsatisfactory outcome
(table 7). In the 40–66 age group, a potentially
unsatisfactory outcome was 0.2 times (95% CI
0.1–0.9) less likely than in the reference age group
0–27 years. When adjusted for all other predictors
the age effect became weaker (0.4; 95% CI 0.1–1.6)
and no longer significant. Sex was not a predictor
of treatment outcome either in the simple or mul-
tivariate model. Foreign-born patients were 3.2
times more likely to have a potentially unsatisfac-
tory outcome than Swiss-born (95% CI 1.5–6.5).
This effect became insignificant in the multivari-
ate analysis. “Legal status” was the strongest pre-
dictor of a potentially unsatisfactory outcome.
“Legal status” was, however, closely associated
with age, sex and geographic origin. Two cate-
gories of legal status accounted for most of this ef-
fect: “other and unknown”, a category including
irregular aliens, and “asylum seekers and refu-
gees”. These effects became less marked in the
multivariate analysis, and only “other and un-
known legal status” remained significant (adj. OR:
8.8; 95% CI 1.4–53.7). These changes in the effect
estimates indicate multi-colinearity in the predict-
ing variables.
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Discussion
This study is the first in Switzerland to assess
the nationwide results of treatment for TB, the
prime measure of TB control. Overall, the pro-
portion of successful treatment outcomes (79%) is
reassuring. However, specific problems in some
segments of the foreign-born population exist,
such as a 12% default rate among asylum seekers
and a 43 % transfer rate among foreigners of other
status than asylum seekers and foreign labour.
Two previous Swiss studies of TB treatment
outcomes were each limited to one canton [10, 11].
Both showed a slightly lower proportion of suc-
cessful outcomes (70% and 75% respectively).
One of them showed a high proportion of default-
ers (16%) and fewer than 1% of patients trans-
ferred out of the region; it also showed that for-
eign patients had an unsatisfactory outcome more
often than Swiss patients [11]. The other study
showed 4% defaulters and 7% transfer out [10].
In other western European countries and in
the USA, the proportion of successful results was
similar to that in this study [8, 13, 14]. A low pro-
portion of proven cure is common. It is related to
the difficulty of obtaining a sputum sample at the
end of the treatment, as patients have stopped
coughing. Therefore, most of the cases classified
as “successful outcome” have only completed their
treatment without final proof of cure. Neverthe-
less, based on these results, the future Swiss guide-
lines for the treatment of tuberculosis will include
a firm recommendation to confirm the bacterio-
logical cure of all cases with a positive sputum
smear before treatment. It is also common in
Western countries with a low incidence that the
WHO target of 85% successful outcomes is missed
due to a high proportion of deaths in native eld-
erly patients, mostly due to causes other than TB
[8]. In foreign-born patients, who are usually
younger, the death rate is low but the target is
missed due to a high proportion of patients leav-
ing Switzerland before or during treatment. This
is particularly the case among foreigners belong-
ing to groups other than foreign labour and asy-
lum seekers.
The methods used in this study comply with
international standards, so that comparisons with
other countries are possible [11]. As insufficient re-
sults of sputum microscopy are available from no-
tification data, only cases with positive sputum cul-
tures were enrolled and analysed. Two thirds of the
cases in this group also had positive sputum mi-
croscopy, so these cases were likely to be the most
infectious and thus most relevant for the spread of
TB. As the cases with positive sputum smear but
negative culture may have been infected with non-
tuberculous mycobacteria, these were excluded
from the analysis. As the specimens collected be-
fore the beginning of treatment were considered,
this is probably not an effect of treatment. 
Four out of five patients received at least 6
months’ combined therapy within 10 months of
the start of treatment. Treatment failures were
rare, a fact possibly related to the low proportion
of drug-resistant isolates. An underestimate of the
number of treatment failures as defined by the
WHO is possible if cultures were not performed
after 5 months’ treatment in suspicious cases, but
should be a very rare event except in patients leav-
ing the country and eluding further control. De-
faulters were also rare, a fact which may reflect the
high standard of care in the curative sector in com-
bination with the nursing teams specialised in TB
control in some parts of the country. However,
specific problems are observable: defaulters are ap-
parently met with mainly among asylum seekers.
In the Netherlands, asylum seekers were also
among the groups at higher risk for default [15].
Default from treatment ultimately reduces the ef-
fectiveness of the screening programme in place
for this group, which is aimed at stopping trans-
mission by early detection and treatment. More di-
rectly observed treatment (DOT) to ensure drug
intake in this group is needed. As this group is also
highly mobile within the country, it should be a
focus for specialised nursing teams who establish a
culturally sensitive relationship to ensure follow-
up and drug intake until completion of treatment,
if necessary with the aid of incentives (tickets for
transportation, free meals, etc.). It cannot be ruled
out that some of the defaulters among the foreign
population have actually left the country (volun-
tarily or by legal decision). If some stay illegally in
the country, they may avoid all contact with the
health care system. Patients leaving the country
may contribute to the spread of TB elsewhere and
to local drug resistance. Coordination of the dif-
ferent actors involved could also cut health care
costs by reducing the number of physicians and
hospitals involved in the course of a treatment.
The WHO recommends that data on treat-
ment results be routinely collected at the local level
as a part of epidemiologic surveillance [3]. Norway
and the Czech Republic have implemented a sys-
tem for mandatory notification of the results of TB
treatment [16]. Experience with our study has
shown that it is difficult for a central surveillance
unit to retrospectively obtain follow-up data from
private practitioners in Switzerland. It was less dif-
ficult wherever there was a local public health team
coordinating and following up patients under
treatment. Public health structures are presently
not sufficient to allow routine monitoring of 
TB treatment outcomes at the national level as 
recommended by the WHO [3, 17]. The main 
reasons are a Federal system with decentralised 
responsibilities in TB control and, in most parts 
of Switzerland, a lack of public health nurses spe-
cialised in TB to be responsible for routine follow-
up of TB patients. 
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